MyoVista wavECG Clinical Evaluation: >=60 y/o Enrichment Population

Health Screening Clinical Trial

Official title:

MyoVista wavECG Clinical Evaluation: >=60 y/o Enrichment Population

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05364541
• Other study ID #: HS-CLINVAL-002
• Status: Active, not recruiting
• Phase: N/A
• Start date: June 1, 2022
• Est. completion date: November 30, 2023

Study information

• Verified date: February 2023
• Source: Heart Test Laboratories, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single-center, interventional, single arm clinical study of the MyoVista wavECG for the detection of LV relaxation abnormalities. The study will be conducted at a single investigational site within the United States. Study subjects will predominately be screened from among those who have been enrolled in prior registry studies by the institution.

Description:

The study has a planned enrollment of at least 50 subjects to obtain approximately 40 subjects with a "normal" septal and lateral e' value on echocardiogram. The criteria defined as septal e'< 7 cm/s or lateral e'< 10 cm/s for relaxation abnormality based on ASE/AECVI guidelines will be used for the evaluation of LV diastolic function which is associated with abnormal relaxation in echocardiography. An independent Core Lab will verify all septal and lateral e' values on the site-acquired echocardiograms and these Core Lab measurements will serve as the ground truth standard with regard to the presence of LV relaxation abnormalities.

Analysis of data from a prior multi-center study has revealed good correlation between the MyoVista wavECG results and echocardiography for the presence of LV relaxation abnormalities. This current study (HS-CLINVAL-002) is intended to supplement data collected in prior and ongoing studies, namely HS-CLINVAL-001, by recruiting individuals who are >60 years old and who are anticipated to have normal echocardiogram results based on a screening of selected clinical characteristics. Subjects in this study will be invited to participate and receive non-standard-of-care echocardiograms and a study driven MyoVista test.

The study will continue to focus on LV relaxation abnormalities by gathering additional device validation data for the purposes of regulatory approval peer-reviewed publications. Echocardiograms of study subjects will be used to compare/validate the study findings.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 50
• Est. completion date: November 30, 2023
• Est. primary completion date: July 15, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 60 Years and older

Eligibility

Inclusion Criteria:

• Subject is >=60 years of age

• Subjects will predominately be recruited among those who are already enrolled in existing registry studies within the institution.

• The subject provides written informed consent using an Informed Consent Form that is reviewed and approved by the site's Institutional Review Board (IRB).

• Conventional ECG results show a sinus rhythm and no other contraindicated rhythm abnormalities (see exclusions below).

Exclusion Criteria:

• The subject has current acute coronary syndrome, decompensated heart failure or stroke

• The subject has received any prior cardiac interventions or surgical therapeutic procedures relating to cardiac abnormalities: valve replacement, pacemaker implantation, coronary artery bypass grafting (CABG), heart transplant, ablation, coronary stent placement, etc.

• Conventional ECG results indicating a lack of sinus rhythm and/or any other contraindicated rhythm abnormalities, including: active atrial fibrillation or atrial flutter, left anterior fascicular block, left and/or right bundle branch block

• The subject is pregnant at the time of the study testing

• The subject has chest deformities that interfere with accurate measurement of ECG (either conventional or wavECG)

• Subjects with central nervous system or musculoskeletal abnormalities that may interfere with accurate acquisition of ECG and/or echocardiogram measurements.

• The subject is enrolled in another clinical study that may interfere with MyoVista or echocardiogram measurements. Exceptions to this may be approved by HeartSciences.

Related Conditions & MeSH terms

• Health Screening

Intervention

Device:
• MyoVista wavECG
A standard 12-Lead, multi-channel resting interpretive trans-thoracic electrocardiograph providing both a Glasgow Interpretive Analysis and unique MyoVista wavECG Information for the detection of Left Ventricular Diastolic Dysfunction.

Locations

Country	Name	City	State
United States	University of Texas Medical Center	Dallas	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Heart Test Laboratories, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Diagnostic Performance	Sensitivity and specificity of the MyoVista for the classification of Low e' where a "positive" includes a MyoVista wavECG result of Positive and Highly Positive. The study result will be considered to have achieved the pre-specified performance criteria for success if the sensitivity is demonstrated to exceed 70% and the specificity is demonstrated to exceed 70%.	Baseline